ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
COVID vaccines

India's Bharat Biotech says vaccine 93.4% effective on severe COVID

Finding shows possibility of boosting people's acceptance of Covaxin

India's homegrown vaccine also showed 77.8% effectiveness against symptomatic COVID-19.   © Reuters

Phase III trials of a vaccine made by India's Bharat Biotech showed it was 93.4% effective against severe symptomatic COVID-19, the firm said on Saturday, a finding that could boost people's acceptance of Covaxin.

The data demonstrated 65.2% protection against the Delta variant, first identified in India, that led to a surge in infections in April and May, and the world's highest daily death tolls.

India's homegrown vaccine also showed 77.8% effectiveness against symptomatic COVID-19 in the trial.

Last month, vaccine maker AstraZeneca Plc also said its vaccine was effective against the Delta and Kappa variants, citing a study.

India has been administering the AstraZeneca vaccine, made domestically by the Serum Institute of India, which said last month it planned to step up monthly production in July to nearly 100 million doses.

Bharat Biotech now estimates it will make 23 million doses a month.

The Phase-III data came as Ocugen Inc, which is codeveloping Covaxin with Bharat Biotech for the U.S. market, prepares to file a request for full U.S. approval.

India, with a tally of 30.45 million infections, is the second most affected nation after the United States, with 33 million. The South Asian nation's death toll has now crossed 400,000.

(Reuters)

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more